Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?

José Miguel Rivera-Caravaca; María Asunción Esteve-Pastor

doi:10.1055/s-0039-3400274

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2019; 119(12): 1891-1893
DOI: 10.1055/s-0039-3400274

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?

Autor*innen

José Miguel Rivera-Caravaca

¹Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red-Enfermedades Cardiovasculares (CIBERCV), University of Murcia, Murcia, Spain

²Faculty of Nursing, Catholic University of Murcia (UCAM), Murcia, Spain
María Asunción Esteve-Pastor

¹Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red-Enfermedades Cardiovasculares (CIBERCV), University of Murcia, Murcia, Spain

Abstract

Volltext

Referenzen

References
1 Benjamin EJ, Blaha MJ, Chiuve SE. , et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association. Circulation 2017; 135 (10) e146-e603
2 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385 (9963): 117-171
3 Göbel S, Prochaska JH, Eggebrecht L. , et al. Management of oral anti-coagulation in patients with heart failure-insights from the ThrombEVAL study. Thromb Haemost 2018; 118 (11) 1930-1939
4 Shah KS, Xu H, Matsouaka RA. , et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 2017; 70 (20) 2476-2486
5 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
6 Sarhene M, Wang Y, Wei J. , et al. Biomarkers in heart failure: the past, current and future. Heart Fail Rev 2019; 24 (06) 867-903
7 Sulzgruber P, Koller L, Winter MP. , et al. The impact of CD4⁺CD28^null T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure. Thromb Haemost 2017; 117 (02) 349-356
8 Richter B, Koller L, Hohensinner PJ. , et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 2012; 108 (06) 1220-1227
9 Zakai NA, Olson NC, Judd SE. , et al. Haemostasis biomarkers and risk of intracerebral haemorrhage in the REasons for Geographic and Racial Differences in Stroke Study. Thromb Haemost 2017; 117 (09) 1808-1815
10 López P, Rodríguez-Carrio J, Martínez-Zapico A. , et al. Serum levels of anti-PON1 and anti-HDL antibodies as potential biomarkers of premature atherosclerosis in systemic lupus erythematosus. Thromb Haemost 2017; 117 (11) 2194-2206
11 Mjelva OR, Svingen GFT, Pedersen EKR. , et al. Fibrinogen and neopterin is associated with future myocardial infarction and total mortality in patients with stable coronary artery disease. Thromb Haemost 2018; 118 (04) 778-790
12 Molvin J, Jujic A, Bachus E. , et al. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients. ESC Heart Fail 2019;
13 Stienen S, Salah K, Moons AH. , et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation 2018; 137 (16) 1671-1683
14 Winter MP, Kleber ME, Koller L. , et al. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction. Thromb Haemost 2017; 117 (03) 471-478
15 Mueller C, McDonald K, de Boer RA. , et al; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21 (06) 715-731
16 Ponikowski P, Voors AA, Anker SD. , et al; ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27) 2129-2200
17 Yancy CW, Jessup M, Bozkurt B. , et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70 (06) 776-803
18 Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33 (05) 1424-1426
19 van den Berg VJ, Bouwens E, Umans VAWM. , et al. Longitudinally measured fibrinolysis factors are strong predictors of clinical outcome in patients with chronic heart failure - the Bio-SHiFT study. Thromb Haemost 2019; 119 (12) 1947-1955
20 Rivera-Caravaca JM, Esteve-Pastor MA, Marín F. , et al. A propensity score matched comparison of clinical outcomes in atrial fibrillation patients taking vitamin K antagonists: comparing the “real-world” vs clinical trials. Mayo Clin Proc 2018; 93 (08) 1065-1073
21 Kozieł M, Potpara TS, Lip GYH. Using blood biomarkers to identify atrial fibrillation-related stroke. Stroke 2019; 50 (08) 1956-1957
22 Rivera-Caravaca JM, Marín F, Vilchez JA. , et al. Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores. Stroke 2019; 50 (06) 1372-1379